The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.
about
Epigenetic therapy in gastrointestinal cancer: the right combinationSerrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapyDifferent definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic reviewBRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapiesMolecular phenotypes of colorectal cancer and potential clinical applicationsThe molecular background of mucinous carcinoma beyond MUC2The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastasesIGFBP3 methylation is a novel diagnostic and predictive biomarker in colorectal cancer.CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.CpG island methylator phenotype and prognosis of colorectal cancer in Northeast China.Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers.Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis.Promoter hypermethylation of tumour suppressor genes as potential biomarkers in colorectal cancer.Correlation between smoking history and molecular pathways in sporadic colorectal cancer: a meta-analysis.Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX.Tracking the Correlation Between CpG Island Methylator Phenotype and Other Molecular Features and Clinicopathological Features in Human Colorectal Cancers: A Systematic Review and Meta-Analysis.CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer.How many diseases are colorectal cancer?Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors.Estimated mean sojourn time associated with hemoccult SENSA for detection of proximal and distal colorectal cancer.Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer.Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer.Prognostic and predictive value of CpG island methylator phenotype in patients with locally advanced nonmetastatic sporadic colorectal cancer.Epigenetic biomarkers in colorectal cancer diagnostics.Genomics and epigenomics of colorectal cancer.DNA methylation and personalized medicine.Luminally expressed gastrointestinal biomarkers.The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer.DNA methylation aberrancies as a guide for surveillance and treatment of human cancers.Expression status of wild-type HSP110 correlates with HSP110 T17 deletion size and patient prognosis in microsatellite-unstable colorectal cancer.Methylation subtypes and large-scale epigenetic alterations in gastric cancer.Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.Colorectal cancer: epigenetic alterations and their clinical implications.DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies.Infrequently expressed miRNAs influence survival after diagnosis with colorectal cancer.Colorectal cancer-susceptibility single-nucleotide polymorphisms in Korean population.CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.Annexin A10 expression correlates with serrated pathway features in colorectal carcinoma with microsatellite instability.CpG island methylator phenotype of myelodysplastic syndrome identified through genome-wide profiling of DNA methylation and gene expression.
P2860
Q26745709-2D5A913C-9A60-4B62-9AD3-74AD3C8A3A4FQ26751035-5B7A1607-4873-4444-A5A9-5905DF516231Q26768471-9BF0B488-7A44-43C0-B72A-34C2939CF3B6Q26772276-9D2BE53E-7590-463A-930A-10344ED65E25Q26785725-675F3810-52F5-43EA-8E4C-5ADB1D9DF0A9Q28083904-D041C86A-AAB7-4730-96D3-314B31C0DE3AQ33630343-79E91AFF-FCE3-48D0-9193-B30B974DCA59Q34050656-DF824C7D-5DDA-49F2-9F1C-74C4CC5EC9DAQ34084652-7F58F0C9-5771-49E7-A327-E45F854373A5Q34177058-C94C9EAE-8DA9-4AA2-A7DF-81DA20BAF11EQ34487177-AC8EB53E-7278-4517-8BDF-97B240489FDBQ34553646-11DCEA1D-3C9B-43BE-A4C7-FB81B29B6512Q35138892-6F960979-7833-4E3C-A46C-E852C768ACDFQ35643491-7DF933D7-AF9F-4C88-90FE-F6E33946EF1DQ35831602-234E8B06-5872-4C3F-9415-0CC420D8B5BAQ35952149-3F1C17C6-94F1-4A01-97F3-D52BF08CDD6BQ36075933-DAFC4D75-7E29-45EC-8D0E-990ED44C4C85Q36238965-A6ED4646-B20A-41C1-8557-72F87B241A21Q36463826-63F0E52D-F1E8-44E9-95DB-0C781ED13941Q36569142-F05CDCC1-25BC-49AD-A3E8-DD1C2C0B0091Q36893961-667178D1-F3A9-4773-B8AB-AFF471D82781Q37100708-AAE7508E-9F84-4345-B2ED-82108FD311C0Q37708015-EB67CC18-9831-459F-AB07-7CD47491AAC7Q37733784-EBCB84E9-D98B-415E-98DB-F32BA7E1C15EQ38018997-8A1242A3-4A2F-4986-9666-B9EF7302199DQ38074617-A804F2BB-AD35-4826-8823-0254E7EB874DQ38250428-8EC1F7EE-DB47-450E-8D36-E80B1581D7ABQ38636313-D94460CF-E3FD-4109-8074-50E7DDC1A0D4Q38730744-3DD8E4C5-D392-4E8D-973D-E956DEA11BB1Q39208639-46309AA9-8349-4010-8885-C6FAD23BEFA8Q43572389-A940B9AF-1782-48E7-8E59-28B1D1CDEBCDQ43936243-BA5ECA3F-431F-4CC6-840F-3F7D747E328AQ45141920-E3183DFB-9956-4F77-BBB7-122875230CBFQ46112381-0468D2AF-A14F-4333-B93A-C9356C4401E2Q46181764-4092DE43-5B34-48B0-B6F0-BCF84CF8252AQ46465597-42CBC56F-FA2B-4F1B-B03E-C3B17E7FE388Q47960541-C8ECE705-EB41-451B-9E07-41C1453B7FF8Q50607666-EE016C60-9E53-47A1-95A3-35B4EC2A754DQ51135450-CB96D859-35D9-42A2-A5C8-AEDB80F2EA50Q54219654-CA4994F3-8C22-4096-9C18-C08D3CCC21F1
P2860
The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The CpG island methylator phen ...... e-based adjuvant chemotherapy.
@ast
The CpG island methylator phen ...... e-based adjuvant chemotherapy.
@en
type
label
The CpG island methylator phen ...... e-based adjuvant chemotherapy.
@ast
The CpG island methylator phen ...... e-based adjuvant chemotherapy.
@en
prefLabel
The CpG island methylator phen ...... e-based adjuvant chemotherapy.
@ast
The CpG island methylator phen ...... e-based adjuvant chemotherapy.
@en
P2093
P2860
P356
P1433
P1476
The CpG island methylator phen ...... e-based adjuvant chemotherapy.
@en
P2093
Byung-Hoon Min
Cheol Keun Park
Dong Kyung Chang
Eui Jin Lee
Hee Cheol Kim
Hong Suk Yu
Jeong Mo Bae
Kyoung-Mee Kim
Suk-Hee Lee
Young-Ho Kim
P2860
P2888
P356
10.1186/1471-2407-11-344
P407
P577
2011-08-10T00:00:00Z
P5875
P6179
1044957790